engin keep get stronger train
continu right track
esrx releas earli read current sell season contract retent
rate posit indic improv fundament combin
success potenti share gain result nois surround
pend aet acquisit well management cost save initi
suggest esrx see modest growth acceler
translat multipl expans
result guidanc summari street esrx beat
consensu top-lin bottom-lin primarili result
stronger expect adj retail claim ebitda per adj claim
management expect ep midpoint slightli consensu claim
slightli lower impli anoth quarter better expect ebitda/rx
management maintain guidanc project includ bonus-pool
relat expens suggest core trend improv sinc compani gave
initi ebitda guidanc dec
earli look retent point improv trend new contract
opportun emerg esrx earli read contract retent sell
season notabl posit highlight improv fundament
strongest retent rate seen sinc coupl expect
improv new contract win success -- partli driven perceiv disruption/distract
pend aet acquisit bring -- like upcom contribut
recent evicor acquisit point stabl acceler growth outlook
esrx
busi continu improv cost effici program yield
meaning result peel back layer esrx core busi continu improv
see highest quarterli annual ebitda margin
perform spite declin adj rx suggest improv profit given
new cost effici program potenti claim growth acceler improv gener
purchas continu believ esrx abl deliv lt ebitda
growth target ex-antm translat ep growth
rais pt believ esrx trade in-lin histor average ntm p/
 discount vs yield pt appli antm-adjust
pro-forma ep risk overhang
ep exclud non-recur charg intang amort pro-forma ep adj contract
loss exhibit
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
page
pleas see import disclosur inform page report
 dollar thousand unless otherwis indic -fiscal year end growth product sg interest expens incom other/equ incom incom non-control averag dilut ep growth growth size statementnet product sg interest expens incom incom statisticstot adjust growth profit/adj growth
page
pleas see import disclosur inform page report
 dollar thousand unless otherwis indic -fiscal year end growth product sg interest expens incom other/equ incom incom non-control averag dilut ep growth growth size statementnet product sg interest expens incom incom statisticstot adjust growth profit/adj growth
page
pleas see import disclosur inform page report
 dollar thousand unless otherwis indic -fiscal year end cash cash st receiv expens current total current asset intang asset total rebat expens portion long-term total current term liabil
esrx statement flow
page
pleas see import disclosur inform page report
 dollar thousand unless otherwis indic -fiscal year end non-cash work flow invest use invest stock issuanc financ financ provid financ exchang translat increas decreas begin end esrx
esrx nation provid pharmaci benefit manag servic plan sponsor includ employ manag care organ
worker union state feder govern pbm esrx offer complet suit servic includ basic claim process
formulari develop manag diseas manag mail-ord pharmaci specialti pharmaci
brian tanquilut certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
bryan ross cfa certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
jason plagman certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
case jefferi employe analyst respons coverag financi instrument discuss report receiv
compens base part overal perform firm includ invest bank incom seek updat research
appropri variou regul may prevent us asid certain industri report publish period basi larg major
report publish irregular interv appropri analyst judgement
articl articl
